INT176131

From wiki-pain
Revision as of 10:29, 20 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.15
First Reported 2004
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.08
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (AKT1, PIK3CG) cytosol (AKT1, PIK3CG) plasma membrane (AKT1, PIK3CG)
cell differentiation (AKT1) nucleoplasm (AKT1) transport (AKT1)
AKT1 (Homo sapiens)
PIK3CG (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 4 16.08 Low Low
cytokine 4 5.00 Very Low Very Low Very Low
positron emission tomography 4 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
cINOD 2 5.00 Very Low Very Low Very Low
peripheral neuropathy 2 5.00 Very Low Very Low Very Low
Inflammatory response 1 5.00 Very Low Very Low Very Low
Bioavailability 1 5.00 Very Low Very Low Very Low
agonist 1 5.00 Very Low Very Low Very Low
cva 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 54 99.52 Very High Very High Very High
Endometrial Cancer 20 97.60 Very High Very High Very High
Solid Tumor 6 91.36 High High
Diabetes Mellitus 2 80.56 Quite High
Hyperglycemia 2 79.60 Quite High
Diarrhoea 6 74.80 Quite High
Appetite Loss 4 74.00 Quite High
Fatigue 9 72.88 Quite High
Pressure And Volume Under Development 2 69.32 Quite High
Fever 5 68.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
PI 3-K/Akt inhibition with Wortmannin significantly decreased NF-?
Akt Neg (inhibition) Binding (inhibition) of PI 3-K
1) Confidence 0.15 Published 2004 Journal Mol Cancer Section Body Doc Link PMC394342 Disease Relevance 0.25 Pain Relevance 0
PI3K, AKT, and mTOR have been targeted individually by various drugs, but XL765 is the first oral dual PI3K and mTOR inhibitor with Phase I trial results, reported by Papadopoulos et al [25].
AKT Binding (targeted) of PI3K
2) Confidence 0.13 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2647552 Disease Relevance 0.82 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox